髂股静脉支架内再狭窄概述
本文综述髂股静脉支架内再狭窄(ISR)的病理、诊断与管理。ISR指支架腔内狭窄,需与支架受压区分,分软、硬病变,对球囊扩张反应不同。支架流入道与剪切应力为重要因素。再干预应基于症状而非影像数值,总体支架闭塞罕见,无症状ISR不推荐预防性球囊扩张。现有治疗多耐久有效,但预防ISR及抗血小板/抗凝作用需进一步研究。
要点
- ISR指支架内狭窄致管腔变窄,需与支架受压区分,分软、硬病变。
- 再干预应基于残余或复发症状,而非单纯影像数值。
- 无症状ISR不推荐预防性球囊扩张,总体支架闭塞罕见。
核心结论
- ISR再干预应基于残余或复发症状而非影像数值,总体支架闭塞罕见,无症状ISR无预防性球囊扩张指征。
- 现有ISR治疗多耐久有效,但预防ISR的方法及抗血小板/抗凝药物的作用需进一步研究。
- 高危血栓后患者可考虑抗凝预防ISR,三联疗法(抗凝联合双联抗血小板)预防ISR的作用尚不明确。
研究设计与样本
- 检索PubMed和Cochrane Library的英文研究,关键词为「in-stent restenosis」「vein」「venous」「iliac」「iliofemoral」,纳入涉及ISR病理、诊断和当前管理选项的相关报告。
主要发现
- ISR指支架内狭窄导致管腔口径变窄,应与支架受压区分。
- ISR分软病变和硬病变两型,对球囊扩张反应不同。
- 支架流入道和剪切应力是ISR发生的重要因素。
- 现有治疗选项包括球囊扩张(超扩张或等扩张)、激光消融、斑块旋切和Z型支架置入。
- ISR所致总体支架闭塞罕见。
关键数值与推荐
- ISR在髂股静脉支架术后患者中报告发生率>70%。
临床怎么用
- ISR再干预应根据残余或复发症状决定,而非仅凭影像学数值。
- 无症状ISR不推荐预防性球囊扩张。
- 高危血栓后患者可考虑抗凝预防ISR。
- 三联疗法(抗凝联合双联抗血小板)预防ISR的作用尚不明确。
局限性
- ISR在髂股静脉支架中常发生但尚未被充分描述。
- 预防ISR方法的研究仍需更多。
- 抗血小板和抗凝药物预防ISR的作用需进一步研究,尤其需关注血栓后与非血栓性髂静脉病变患者亚组。
- 三联疗法预防ISR的作用尚不明确。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Although endovenous stents have been associated with overall low morbidity, they can require reinterventions to correct stent malfunction due to in-stent restenosis (ISR). ISR has often occurred iliofemoral venous stents but has not been well described. It has been reported to develop in >70% of patients who have undergone iliofemoral venous stenting. We sought to provide an overview of ISR in iliofemoral venous stents, including the pathologic, diagnostic, and management considerations and the identification of several areas of potential research in the future. METHODS: A search of reported English-language studies was performed in PubMed and the Cochrane Library. "In-stent restenosis," "vein," "venous," "iliac," and "iliofemoral" were used as keywords. The pertinent reports included in the present review had addressed the pathology, diagnosis, and current management options for ISR. RESULTS: ISR refers to the narrowing of the luminal caliber of the stent owing to the development of stenosis inside the stent itself. ISR should be differentiated from stent compression. Two main types of ISR have been described: soft and hard lesions. These lesions respond differently to angioplasty. Stent inflow and shear stress are important factors in the development of ISR. The treatment options available at present include balloon angioplasty (hyperdilation or isodilation), laser ablation, atherectomy, and Z-stent placement. CONCLUSIONS: Reintervention for ISR should be determined by the presence of residual or recurrent symptoms and not simply by a numeric value obtained from an imaging study. Overall stent occlusion due to ISR is rare, and no role exists for prophylactic angioplasty to treat asymptomatic ISR. The current treatment options for ISR are mostly durable and effective. However, more research is needed on methods to prevent the development of ISR. The role of antiplatelet and anticoagulant agents in the prevention of ISR requires further investigation, with particular attention to unique subset of patients (after thrombosis vs nonthrombotic iliac vein lesions). For high-risk, post-thrombotic patients, anticoagulation can be considered to prevent ISR. The role of triple therapy (anticoagulation and dual antiplatelet therapy) in the prevention of ISR remains unclear.
引用
- Saleem T, Raju S. An overview of in-stent restenosis in iliofemoral venous stents. J Vasc Surg Venous Lymphat Disord. 2021. PMID: 34774813. doi:10.1016/j.jvsv.2021.10.011
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。